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ENGLISH SUMMARY 
Venous thromboembolism (VTE) constitutes deep vein thrombosis and pulmonary 
embolisms, obstructing central or peripheral lung arteries. VTE can occur unprovoked 
or provoked by known risk factors. The association between surgery and VTE is well 
recognized in previous investigations that found these complications preventable with 
pharmacologic and mechanical prophylaxis. Since, surgical techniques have 
improved and it has been proposed that e.g. minimally invasive surgery is associated 
with a lower risk of VTE.  
Recently, cancer-associated VTE has gained increased attention and numerous studies 
have examined suggested risk factors and biomarkers for predicting the risk in cancer 
patients. Some cancer types are associated with higher VTE risk than others, ovarian 
cancer being one of them.  
This thesis examines the incidence of VTE in different risk groups within the 
gynecology specialty. Study I showed a low incidence of VTE following 
hysterectomy, especially if performed with a minimally invasive technique and if 
postoperative prophylactic low molecular weight heparin was administered. With the 
available study population in study II we were not able to show a difference in 
postoperative VTE risk when comparing hysterectomy for benign conditions to 
patients with endometrial cancer as the primary indication for hysterectomy. Study III 
examined the incidence of VTE in all patients diagnosed with ovarian cancer during 
a 10-year period in Denmark. The result showed a high incidence of VTE, especially 
within the first year after cancer diagnosis. We identified several risk factors, e.g. that 
VTE risk was increased following surgery and chemotherapy. In study IV, women 
with suspected ovarian cancer, referred to Aalborg University Hospital, were followed 
with objective examinations for VTE one year after first referral. The incidence of 
VTE at the time of first referral was lower than expected, although the cumulative 
one-year VTE incidence was high in women with confirmed ovarian cancer. A notable 
proportion of women were diagnosed with VTE in relation to non-surgical treatment 
for ovarian cancer.  
These results contribute with new insights into the risk of VTE after gynecologic 
surgery and VTE risk factors in relation to ovarian cancer. Clinical trials are warranted 
before modification of current guidelines on postoperative VTE prophylaxis. 
Molecular biology research will potentially contribute to a better understanding of the 
mechanisms behind the proposed disturbance in the homeostasis of the coagulation 
system in ovarian cancer.  
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DANSK RESUME 
Venøs tromboemboli (VTE) er en samlet betegnelse for blodpropper, der opstår i 
kroppens dybe vener eller lungeemboli, som obstruerer centrale eller perifere arterier 
i lungerne. VTE kan opstå uden kendt årsag eller være provokeret af kendte 
risikofaktorer. Sammenhængen mellem VTE og operation er velkendt og undersøgt i 
mange tidligere studier, som også viste, at disse komplikationer kunne forebygges 
medicinsk og mekanisk. Der er sket store forbedringer inden for operationsteknikker, 
siden mange af disse studier er udført, og meget tyder på, at blandt andet minimalt 
invasiv kirurgi er forbundet med en lavere VTE risiko.  
Der har i de senere år været øget fokus på cancer-associeret VTE, og mange studier 
har undersøgt mulige risikofaktorer og biomarkører til forudsigelse af, om en patient 
er i særlig høj risiko. Nogle kræfttyper er forbundet med højere VTE risiko end andre, 
herunder æggestokkræft. 
Denne afhandling undersøger forekomsten af VTE i forskellige risikogrupper 
indenfor det gynækologiske speciale. Studie I viste en lav VTE forekomst efter 
operativ fjernelse af livmoderen, specielt efter minimalt invasiv kirurgi og hvis der 
blev givet forebyggende lavmolekylært heparin efter operation. I studie II kunne vi i 
den tilgængelige studiepopulation ikke påvise en forskel i VTE risiko efter operation 
ved sammenligning af kvinder, som fik fjernet livmoderen på grund af godartet 
sygdom, med kvinder, som havde livmoderkræft som årsag til fjernelse af livmoderen. 
Studie III undersøgte forekomsten af VTE hos alle patienter med æggestokkræft i 
Danmark diagnosticeret inden for en 10-årig periode. Resultatet viste en høj 
forekomst af VTE især det første år efter cancerdiagnosen. Vi identificerede flere 
risikofaktorer og fandt blandt andet, at risiko for VTE var øget i perioder efter 
operation og kemoterapi. Studie IV fulgte kvinder henvist til Aalborg 
Universitetshospital på mistanke om æggestokkræft med objektive undersøgelser for 
VTE det første år efter henvisning. Forekomsten af VTE på henvisningstidspunktet 
var lavere end forventet, men den sammenlagte et-årige forekomst var høj hos kvinder 
med bekræftet æggestokkræft. Kvinderne blev især diagnosticeret med VTE i 
forbindelse med ikke-kirurgisk behandling for æggestokkræft. 
Disse resultater bidrager med ny viden om risiko for VTE efter gynækologisk 
operation og VTE risikofaktorer ved æggestokkræft. Der er behov for flere kliniske 
studier, før der kan laves nye anbefalinger for forebyggelse af VTE efter operation. 
Indenfor æggestokkræft kan molekylær biologisk forskning potentielt hjælpe til at 
forstå mekanismerne bag den formodede ubalance i blodstørkningssystemet.   
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PREFACE 
“Je suis perdu; une phlegmatia qui vient de se déclarer cette nuit, ne me laisse aucun 
doute sur nature de mon mal.” —Armand Trousseau1  
“I am lost; a phlebitis which has declared itself this night leaves me no doubt about 
the nature of my illness.”  
Armand Trousseau (1801-1867) is recognized for his studies of the association 
between visceral cancer and migratory thrombophlebitis. Trousseau observed, that a 
first sign of cancer could be painful oedema of the lower or upper extremities, also 
known as Trousseau’s syndrome. After retiring from the Faculty of Medicine and the 
hospital Hôtel-Dieu de Paris, he suffered from stomach pain, tiredness, reduced 
appetite and weight loss, but found no palpable abdominal tumor. After developing 
the symptoms of deep vein thrombosis, he was certain that a visceral cancer was the 
cause of his symptoms, and he was right, as gastric cancer caused his death months 
later. Since Armand Trousseau taught medical students about “phlegmasia alba 
dolens”2as an important first sign of cancer, many studies have been conducted to 
investigate cancer-associated thrombosis.3 
This thesis investigates the risk of venous thromboembolism in patients undergoing 
treatment for gynecologic disease, focusing on incidence according to the underlying 
benign or malignant disease. Furthermore, the thesis focuses on patient- and 
treatment-related risk factors. 
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BACKGROUND 
1.1. VENOUS THROMBOEMBOLISM (VTE) 
Pulmonary embolism (PE) with obstruction of central or peripheral lung arteries and 
deep vein thrombosis (DVT) most often located in the deep veins of lower extremities 
constitute venous thromboembolism (VTE).4 VTE episodes are classified as 
provoked, in the presence of a well-known risk factor, or unprovoked in the absence 
of risk factors. Risk factors can be categorized as permanent (e.g. thrombophilia, non-
curable cancer, autoimmune disease) or transient (surgical trauma, hormone 
treatment, pregnancy).5 Unprovoked VTEs are associated with the highest risk of 
recurrence. In a study population without cancer, 20 % with unprovoked first-time 
VTE experienced recurrence, whereas recurrence was 8 % in patients with non-
surgical provoked VTE, and no recurrence after VTEs provoked by surgery.6  
VTEs can also be classified as either symptomatic or asymptomatic, the latter 
observed after examination e.g. in relation to clinical trials or incidental findings on 
radiological imaging performed for other indications than clinically suspected VTE.7 
Virchow (1856) proposed a theory to describe the pathogenesis behind the 
development of venous thrombosis. In an up-to-date terminology, Virchow’s triad 
describes an unbalance between endothelial damage, venous stasis and a 
hypercoagulant state.8 It will often be possible to explain the causation of VTE by 
Virchow´s triad, as depicted in Figure 1.  
 
Figure 1 Components of Virchow's triad: Blood flow, vascular function and blood composition. Bleeding 
or thrombosis occurs in case of unbalance in the regulation of coagulation. II, IX, and X are coagulation 
factors. 
BACKGROUND 
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Symptoms of PE are dyspnoea, tachycardia, chestpain, haemoptysis, or sudden death. 
Acute symptoms of DVT are leg swelling, redness, pain and warmth. A DVT can 
progress to a PE or manifest as post-thrombotic syndrome.9 These symptoms are not 
exclusive for VTE, and therefore, diagnostic tools are important to rule out other 
underlying pathology. 
1.2. DIAGNOSIS, TREATMENT AND PREVENTION OF VTE 
The fibrin degradation product D-dimer can be used to assess the probability of VTE 
in symptomatic patients. The test has a 91 % sensitivity for DVT and 55 % specificity, 
but the performance is influenced by the assay used, as well as patient characteristics. 
Cancer and pregnancy can increase D-dimer levels.10 Furthermore, D-dimer increases 
naturally with age and an age-adjusted threshold has been proposed.9 
Clinical decision rules (CDR) are available to help guide clinicians in the diagnosis 
of VTE. The Wells score is widely used for this purpose in combination with D-
dimer.11,12  Figure 2 illustrates how CDR and D-dimer testing can safely rule out 
patients with a low probability of VTE, without concurrent imaging.  
 
   
Figure 2 Diagnostic algorithm for suspected venous thromboembolism. Modified from12–14                              
*Clinical decision rule e.g. Wells score as illustrated in corresponding table to assess probability of VTE; 
†DVT probability; ≤1 point: Unlikely, >1point: Likely.                                      
‡PE probability; ≤4 points: Unlikely, >4 points: Likely.                          
  
Venography for the diagnosis of DVT is a very sensitive test and has been used as the 
reference standard, but for practical use, it has been replaced by the non-invasive 
ultrasonography, which has a high sensitivity (94 %) for particular proximal DVT 
	
	
	
	
Figure	1;	Flowchart	presenting	the	patient	selection	using	Danish	National	Registries.	
	
	
Negative  Positive 
Negative  
Suspected venous 
thromboembolism (VTE) 
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whereas much lower (64 %) for distal DVT with a 94 % specificity.15 The simplest 
technique for ultrasound scan is performed in grey scale (B-mode) with intermittent 
compression of the deep veins.16 In the presence of a DVT, the vein will be 
incompressible (Figure 3).  
 
Figure 3 Diagnostic imaging for venous thromboembolism. A: Upper series demonstrate the 
configuration of the veins in a patient undergoing CUS with the corresponding ultrasound image below. 
From left to right: The arterial and venous femoral blood vessels are depicted without compression from 
the transducer in the first image, the second image demonstrates total compressibility of the femoral vein 
in the absence of DVT. The third image illustrates increased diameter/lumen, incompressibility and no 
blood-flow in the presence of an occlusive DVT. Picture B shows a central PE in the right pulmonary 
artery and a segmental PE in a branch from the left pulmonary artery. A= Artery, V=Vein. From S.Z. 
Goldhaber, H. Bounameaux, Pulmonary embolism and deep vein thrombosis, Lancet. 379 (2012) 1835–
1846.13 Reprinted with permission from Elsevier. 
Compression ultrasound scan (CUS) can be supplied with modalities such as color 
flow and power Doppler imaging, in order to increase sensitivity.17 The sensitivity in 
asymptomatic cohorts is reported to be 66.7 % for proximal DVT, while only 39 % 
for distal DVT.10 Computed Tomography Pulmonary Angiography (CTPA) has 
become the first-line imaging modality for confirmation of suspected PE, as it has a 
BACKGROUND 
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high diagnostic accuracy and is widely available. The disadvantages of CTPA are the 
exposure to iodized radiation and infusion of contrast medium, which can be 
contraindicated in case of renal impairment.9,12 Improvement of imaging techniques 
has resulted in the detection of smaller pulmonary emboli with potentially no clinical 
relevance.18–20 Clinical surveillance is recommended instead of anticoagulant 
treatment in low-risk patients with sub segmental PE, in the absence of proximal DVT 
by CUS screening.21  
The clinical significance of isolated distal DVT has been subject to discussion, since 
this condition reports lower morbidity and mortality compared to proximal DVT, 
while also having a lower recurrence rate.22 For these patients, clinical surveillance is 
recommended over anticoagulant treatment, to control for proximal extension in case 
of isolated distal DVT in low-risk patients.21  
Before initiating antithrombotic treatment, it should be considered if the VTE is 
unprovoked or provoked by a transient or permanent risk factor, since this should 
guide clinicians in choice of drug and treatment duration.5 The American College of 
Chest Physicians (ACCP) Antithrombotic guidelines provide definite 
recommendations for VTE treatment, regarding anticoagulant drugs and duration, in 
non-cancer patients.21 Non-vitamin K oral anticoagulants (NOACs) are safe and 
efficient for long-term VTE-treatment in non-cancer patients, and are preferred over 
Vitamin K antagonists (VKA) and low molecular weight heparin (LMWH). Guidance 
regarding VTE in cancer patients is less clear; In the absence of major risk of bleeding, 
anticoagulant treatment is recommended as long as cancer is active, but in risk of 
bleeding, complications could possibly outweigh the benefits. Active, solid cancer is 
defined as cancer diagnosed within six months of the VTE event, non-curable cancer, 
active antineoplastic treatment, metastatic or recurrent cancer.23 LMWH is preferred 
over VKA as it has proved to be more effective in the prevention of recurrent VTE in 
patients with active cancer without increasing risk of bleeding complications.24 Safety 
and efficacy of NOACs in cancer patients remains uncertain, and routine use is not 
recommended for treatment of VTE.25 NOACs might be implemented for thrombosis 
prophylaxis during non-surgical cancer treatment in high-risk patients, after the 
CASSINI and AVERT studies proved safety and efficacy for this purpose.26 Evidence 
to guide the decision of the optimal duration is not clear, AY Lee suggests a 
personalized recommendation for every patient, based on current evidence and 
personal preferences.27  Discontinuation of anticoagulant treatment after PE could be 
guided by D-dimer levels, in patients with a low recurrence risk, as suggested by 
Palareti et al. 28 
BACKGROUND 
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1.3. THE RISK OF VENOUS THROMBOEMBOLISM IN THE 
GYNECOLOGIC PATIENT 
Hospitalized patients are generally at increased risk of developing venous 
thromboembolic complications, described as the most common preventable cause of 
hospital death.29 Different factors influencing risk of VTE, can be divided into patient-
related (e.g. gender, age, thrombophilia, obesity, smoking), disease-related (e.g. 
malignancy, inflammatory disease), and treatment-related (e.g. estrogen-containing 
oral contraceptives or hormone therapy, surgery, chemo- and radiotherapy).3,30,31 
Early studies reporting an incidence of DVT between 15-40 % following major 
gynecologic surgery, used sensitive diagnostic tools such as venography and 
radioactive labelled fibrinogen leg-scanning.32,33 Randomized controlled trials 
concluded that many of these symptomatic, as well as asymptomatic VTE cases, could 
be prevented with proper thrombosis prophylaxis.34,35 Recent observational studies 
based on data from clinical databases report incidences of symptomatic VTE between 
0.1-2.2 % after gynecologic surgery for benign conditions and cancer.36–39 Surgical 
technique has been reported to be associated with risk of VTE, with the highest 
incidence in open abdominal- and pelvic surgery and lowest incidence in minimally 
invasive surgery (laparoscopic or vaginal approach). A large cohort study from 
gastrointestinal surgery with 138,595 patients treated for benign conditions found a 
higher risk of VTE in open surgery (0.59 % VTE cases) compared to laparoscopy 
(0.28 % VTEs) with Odds ratio (OR) at 1.8 (95 % CI, 1.3-2.5).40 One reason that 
minimally invasive surgery (MIS) minimizes the risk of VTE might be early 
mobilization and ambulation of patients, which is suggested to play an important role 
in the prevention of VTE.41 
1.4. CANCER PATIENTS AND RISK OF VTE 
Approximately 20% of incidental venous thromboembolic events are cancer related.9 
The impact of VTE on survival was demonstrated by Sørensen et al in a Danish cohort 
study showing overall 1-year survival rates of 12 % in cancer patients diagnosed 
within a year of a VTE event, compared to a survival rate of 36 % in matched cancer 
patients without VTE.42 Some cancer types carry a higher risk than others, these being 
tumors of the pancreas, ovary, brain and bone.43 The effect of advanced stage on VTE 
risk also differs within different cancer types, most evident in uterine cancer. 43,44 
Another important factor associated with risk of VTE is time since cancer diagnosis, 
with the highest incidence observed within the first few months, possibly associated 
to the aggressiveness of tumor biology and initiation of cancer treatment.45 In 
pancreatic cancer, Larsen et al. found that 9 % of patients had VTE upon first 
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admission to hospital in a prospective cohort study with systematic examination for 
both symptomatic and asymptomatic VTE.46 Using the same setup, Stender et al. 
observed 8 % preoperative VTE events in patients with colorectal cancer.47 The 30-
day incidence of VTE following cancer surgery varies from 0.3 % after breast 
resection to 7.3 % after oesophagectomy.48 Patients undergoing chemotherapy are at 
increased risk of VTE43, but evidence to support VTE prophylaxis in the outpatient 
setting is scarce. 49,50 There are divergent reports on the risk of VTE in relation to 
treatment with vascular endothelial growth factor(VEGF)-inhibitor, but a systematic 
review concluded that risk of arterial, but not venous thrombosis, was increased in 
patients exposed to this therapy.51 Central vein catheters induce endothelial damage 
and inflammation, which can lead to deep vein thrombosis at the catheter site. This is 
a common complication in patients undergoing chemotherapy, especially in patients 
with peripherally inserted central catheters or prior history of VTE.52 
1.5. ENDOMETRIAL CANCER  
With almost 100.000 new cases per year in Europe, endometrial cancer is the most 
common gynecological cancer in developed countries, with approximately 800 new 
cases in Denmark annually.53,54 Endometrial cancer primarily occurs in 
postmenopausal women, with a median age of 63 years at diagnosis. The initial 
symptoms are abnormal bleeding or spotting. The primary risk factor is estrogen 
exposure associated with early menarche, late-onset menopause, nulliparity, obesity, 
diabetes, polycystic ovary syndrome, radiation therapy and tamoxifen use.55,56 
Patients with a germline mutation in DNA mismatch repair genes (Lynch Syndrome) 
have an up to 60 % life-time risk of developing endometrial cancer.57 Endometrial 
carcinomas have been classified according to histopathology and molecular biology. 
Most tumors (80-90 %) are classified as type I endometrioid estrogen-dependent 
adenocarcinomas with a favorable prognosis compared to type II tumors comprising 
non-endometrioid carcinomas (e.g. serous, clear cell, undifferentiated).53 Genetic 
mutations are diversely distributed within the two tumor types and molecular insight 
could potentially influence future treatment guidelines and provide targeted medical 
development opportunities.57,58  Most endometrial carcinomas are diagnosed in early 
stage (80 % in International Federation of Gynecology and Obstetrics (FIGO) stage I) 
in which the five-year survival is more than 95 %, in advanced disease survival rates 
are much lower53. Primary treatment is surgical removal of the uterus, salpinges and 
ovaries which can be performed as either open surgery (laparotomy) or MIS, by 
vaginal or laparoscopic (conventional or robotic) access. The indication for more 
extensive surgery including e.g. lymphadenectomy, is guided by stage of disease and 
a preoperative pathological examination of an endometrial biopsy. Lymph node 
dissection (LND) is not indicated in case of endometrioid histotype, differential grade 
1 and 2 and myometrial invasion <50 %.53 
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In two large cohort studies with up to 24 months of follow-up, risk of VTE in 
endometrial cancer was correlated to advanced disease, non-endometrioid 
histopathology, and endometrioid grade 3 carcinomas.59,60 Publications on the 30-day 
postoperative risk of VTE, report a low VTE incidence between 0.35-1.3 %, with the 
lowest risk in patients undergoing MIS.39,61–63 Given the low VTE incidence following 
surgery, it has been proposed that four weeks of extended VTE prophylaxis, as 
recommended by clinical guidelines, is not required for this group of low-risk 
patients.35,64–66  
 
1.6. OVARIAN CANCER; EPIDEMIOLOGY, DIAGNOSIS AND 
TREATMENT 
In 2012, 65.538 women were diagnosed with ovarian cancer in Europe, with the 
highest incidences in northern Europe.67 Approximately 550 Danish women are 
diagnosed with ovarian cancer every year.68 Patients are typical elderly and 
postmenopausal with a median age of 63 years.69  
Non-epithelial ovarian cancer constitutes approximately 10 % of ovarian cancers. 
These include germ cell-, sex cord stromal and pure stromal tumors, that are further 
categorized into histopathological subtypes. Non-epithelial tumors are rare, and 
managed differently from epithelial ovarian cancer (EOC), and will not be discussed 
in further detail in this thesis.70 EOC are classified as high-grade serous (~70 %), 
endometrioid (~10 %), clear cell carcinoma (~5 %), low-grade serous (~5 %) 
mucinous (~3 %), Brenner and undifferentiated carcinomas (Figure 5).71,72 
Histopathological distribution varies between countries, and the proportion of clear 
cell carcinomas accounts for 24 % of EOC in Japan.73  Borderline tumors are tumors 
of low-malignant potential, managed surgically with a low recurrence rate. In recent 
years, it has been commonly recognized that tumor classification has important 
implications on prognosis and treatment. Therefore, it is crucial that histopathological 
examination is carried out by experts in the field of gynecopathology.74,75 
Etiology of the cancer is unknown in most patients, germline mutations (in e.g. BRCA 
or mismatch repair genes) are present in 3-24 %.76 Other risk factors are endometriosis 
and obesity.77 Tubal ligation and factors decreasing ovulations such as pregnancies, 
breastfeeding and hormonal contraceptives, reduce the risk of EOC.78 
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Figure 4 Microscopic images of the major EOC histotypes: A) Serous borderline, B) High-grade serous 
carcinoma, C) Endometriod carcinoma, D) Clear cell carcinoma, E) Mucinous carcinoma, F) Mucinous 
carcinoma, cytokeratin 7 staining. From G.C. Jayson et al. Ovarian Cancer, Lancet. 384 (2014) 1376–
1388.78 Reprinted with permission from Elsevier. 
Symptoms in early stage ovarian cancer are often vague, which might explain that 
most ovarian cancers are diagnosed in advanced stage. Recognized symptoms at all 
stages include abdominal or pelvic pain, vaginal bleeding, affected intestinal function, 
polyuria, abdominal distention, fatigue and DVT.69  
Patients with suspected ovarian cancer undergo gynecologic examination including a 
transvaginal ultrasound scan. Risk of malignancy index (RMI) is calculated based on 
the ultra-sonographic findings, menopausal status and CA-125 level measured in a 
blood sample (illustrated in Figure 5). The most commonly recognized RMI was 
developed by Jacobs et al.79 With a cut-off at 200, the accuracy of RMI in correctly 
diagnosing EOC was previously validated with a 71 % sensitivity, 92% specificity 
and a positive predictive value of 69 % and negative predictive value at 92 % in 
women> 30 years of age, referred with a pelvic mass.80 A slightly different RMI was 
proposed by Tingulstad et al. with a 80 % sensitivity and 92 % specificity.81    
		 
Figure 5 Risk of malignancy index (RMI) score 
Figure 6 Risk of malignancy index (RMI score).  
Ultrasound criteria (U score) Menopausal status (M score) 
Multilokular cyst 1 Premenopausal or prior 
hysterectomy and age  < 50 years  
 
1 Solid areas 1 
Bilateral lesions 1 Postmenopausal or prior 
hysterectomy and age  ≥ 50 years 
 
3 or 4* Ascites 1 
Intraabdominal metastases 1   
Total U-score; 0-1: U=1, 2-5: U=3 or 4* 
 
Formula RMI=U x M x s-CA-125 
Interpretation: RMI < 200: Most likely benign ovarian tumor. RMI ≥ 200: Suspected ovarian cancer 
*Jacobs et al.79 proposed U and M score at 1 or 3, whereas Tingulstad et al.81 described U and M score at 1 or 4.	
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In order to stage the tumor, Computed Tomography (CT), Positron Emission 
Tomography (PET) or magnetic resonance (MR) imaging is performed preoperatively 
in most patients, but is not mandatory.82 An example of a 18F-labeled Fluoro-2-
deoxyglucose (18F-FDG ) PET-CT scan in a patient with FIGO stage IV disease is 
depicted in figure 6.	
  
Figure 6 Whole body PET-CT scan; Illustrating 18F-FDG-uptake throughout the abdominal cavity 
consistent with advanced epithelial ovarian cancer. 
The primary treatment of EOC is surgical resection of all visual tumor tissue. In case 
of advanced disease, neoadjuvant chemotherapy (NACT) followed by secondary 
debulking surgery is optional. This treatment algorithm is supported by recent 
publications with long term follow-up data that demonstrated non-inferiority to 
upfront surgery83. The primary intention should be complete resection of visual tumor 
tissue, since clinical trials have demonstrated this to be the most important prognostic 
factor.84 Adjuvant chemotherapy with paclitaxel and carboplatin is indicated for the 
majority of patients except in the earliest stages of low-grade tumors.82 Based on 
beneficial effects on overall survival in poor-prognosis patients, the angiogenesis 
inhibitor bevacizumab is added in cases of incomplete resection of tumor tissue in 
patients with FIGO stages III/IV.85 A recently published clinical trial, demonstrated 
an increase in progression free survival in EOC patients, treated with a Poly ADP 
Ribose Polymerase (PARP)-inhibitor. Maintenance therapy after concluding 
chemotherapy, is recommended in patients with FIGO stage III/IV high-grade 
serous/endometrioid EOC with BRCA mutations, and complete/partial response to 
platinum-based chemotherapy.86 
Recurrence in EOC patients usually occurs within the first three years after diagnosis 
and the overall five-year survival was 41% in Denmark in the period from 2012-
2016.68
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1.7. OVARIAN CANCER AND RISK OF VTE 
A large number of studies have investigated a proposed procoagulant state that causes 
changes in the constituents of the blood in ovarian cancer patients, and thereby 
increase the risk of VTE87–90 There is a great variation in the reported incidence of 
VTE, which in part can be explained by the study designs. Observational studies 
obviously report lower incidences than prospective clinical trials that use sensitive 
imaging tools to examine for the presence of both symptomatic and asymptomatic 
events. Rodriguez et al investigated VTE incidence in a cohort of 13,031 ovarian 
cancer patients (borderline tumors, epithelial and stromal cancers) based on 
retrospective data retrieved from the California Cancer Registry from 1993-99.91 The 
two-year cumulative incidence of VTE was 5.2 %. Risk factors included disease stage, 
histopathology and degree of comorbidity. Thirty percent of cases were observed 
during the 90-day postoperative period, but the multivariate analysis showed that 
patients who did not undergo surgery were at higher risk, indicating that tumor burden 
is of great importance. VTE incidence at time of diagnosis was reported to be 3.3 % 
in a German study by von Tempelhoff et al using impedance plethysmography for 
DVT screening92, whereas Satoh et al found 25 % VTE cases in a Japanese cohort 
using CUS.93 Both studies included EOC and borderline tumors. Ovarian cancer 
diagnosed in near relation to a VTE episode is associated with a poorer prognosis 
compared to patients with no VTEs.94,95 In one study, neoadjuvant chemotherapy was 
associated with a 11.6 % VTE incidence during treatment period.96 Pant et al. 
observed a 12.5 % VTE incidence in a retrospective cohort of 128 EOC patients 
undergoing first-line chemotherapy after surgery. There was a great variation in 
treatment regimens according to chemotherapy, making comparison to other studies 
difficult.97 
Coagulation markers are often elevated in cancer patients without VTE, indicating 
that the coagulation system is activated even in the absence of a detectable thrombus.98 
Cancer cells are capable of activating the coagulation system in different ways 
including expression of tissue factor, and shedding of procoagulant factors into the 
blood stream (Figure 7).99 Swier et al. reviewed the literature regarding the association 
between ovarian cancer and VTE, and addressed several mechanisms of the 
coagulation components involved in VTE occurrence and cancer progression, 
including possible biomarkers.100 Tissue factor is assumed to play a central role in the 
pathogenesis behind the hypercoagulant state observed in ovarian cancer patients. 
VTE risk varies between different histopathologic subtypes of EOC with the highest 
incidence observed in clear cell carcinomas even in early FIGO stage.101 Elevated 
interleukin-6, increased expression of tissue factor, and shedding of tissue factor 
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bearing microparticles has been observed in clear cell carcinomas and are considered 
to play a role in the increased coagulant activity.102–104 
 
 
Figure 7 Different ways tumor cells induce a hypercoagulant state. From Prandoni et al. Cancer and venous 
thromboembolism, Lancet Oncol. 6 (2005) 401-410.98 Reprinted with permission from Elsevier. 
1.8. BIOMARKERS FOR VTE PREDICTION  
D-dimer is the only biomarker that is routinely used in clinical practice to assess the 
probability of VTE in symptomatic patients. There are several commercially available 
assays that by different techniques localize different epitopes at the D-dimer molecule, 
and the threshold indicating an elevated level vary, making comparison of studies 
difficult.105,106 Performance of the test can be influenced by different factors and 
Schaefer et al. proposed that D-dimer might not be appropriate in certain patient 
groups, including cancer.107 A broad panel of other biomarkers are subject to 
investigation as predictors of VTE. One of the more promising biomarkers to predict 
VTE is P-selectin, a molecule that mediates platelet adhesion to the endothelium and 
induces tissue factor expression on the surface of monocytes.8,108 Cancer cells increase 
the expression of P-selectin on certain cells including endothelial cells. This enhances 
interaction with neoplastic cells, thought to play an important role in the metastatic 
spreading of cancer cells.109 
Different laboratory tests have been investigated by Ay et al. in the Vienna Cancer 
and thrombosis study, with the aim of improving risk stratification in cancer 
patients.110 Soluble p-selectin and thrombin-generation are suggested as promising 
predictors of cancer-associated thrombosis.109,111 
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HYPOTHESES AND AIMS 
Early studies have indicated an association between major pelvic surgery and 
significant venous thromboembolic complications. Hysterectomy is a common 
procedure in gynecology and is performed for a variety of conditions. However, only 
few studies have focused on the risk of a VTE event following hysterectomy indicated 
for benign disease.  
Paper I: To investigate the 30-day risk of VTE in a large population based cohort of 
women undergoing abdominal, laparoscopic and vaginal hysterectomy for benign 
conditions. 
Endometrial cancer is the most common gynecologic cancer in developed countries 
with the majority of cases diagnosed in early stages for whom the prognosis is good 
after treatment with hysterectomy. Clinical guidelines on thrombosis prophylaxis in 
gynecologic oncology surgery have recently implied recommendations to extend 
prophylaxis for all patients for four weeks following major surgery. The null-
hypothesis of study 2 was a similar risk of VTE between patients undergoing 
hysterectomy for endometrial cancer, compared to benign disease.  
Paper II: To determine the incidence of postoperative VTE in endometrial cancer 
patients compared to patients undergoing hysterectomy for benign disease.  
Ovarian cancer is among the cancers with the highest risk of venous thromboembolic 
complications. Many studies have investigated the incidence of VTE in ovarian cancer 
and the impact of person-, tumor- and treatment related risk factors. However, no 
study has focused on exact timing of VTE episodes associated to both person-, tumor- 
and treatment related risk factors. 
Paper III:  To determine at which time epithelial ovarian cancer patients are at highest 
risk of developing venous thromboembolic events. 
The incidence of VTE has primarily been studied in retrospective cohorts. A few 
prospective cohorts, mostly from Japan, report high VTE incidences in ovarian cancer 
even prior to surgery. We hypothesized that the main proportion of VTEs would be 
present at time of first referral for ovarian cancer as asymptomatic events, that could 
become symptomatic after surgery. 
Paper IV: To examine the incidence of symptomatic and asymptomatic venous 
thromboembolism in patients with suspected epithelial ovarian cancer from time of 
diagnosis and throughout the first year, in a prospective, consecutive cohort study. 
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METHODS  
3.1. REGISTERS USED IN STUDY I-III  
CPR: The Danish Civil Personal Registration System; Every Danish resident is 
provided a unique personal civil registration number (CPR-number) at time of birth 
or immigration. The CPR-number is used at all contacts with the health care system, 
which enables linkage of different Danish registers.112  
DNPR: The Danish National Patient Registry covers all hospitalizations in Denmark 
since 1977 and outpatient visits since 1995.113 Accessible information includes dates 
of admission and discharge. Coding of disease follows ICD-8 (international Statistical 
Classification of Diseases, eighth revision) until 1994, where it was replaced by the 
tenth revision (ICD-10). Surgical treatment is registered according to the Nordic 
Medico-statistical Committee’s Classification of Surgical Procedures.114 In 2001, it 
became mandatory to report many medical treatments including cancer treatment. The 
validity of the coding of chemotherapy and bevacizumab was previously validated in 
colorectal cancer with an overall high sensitivity (94-100 %, specificity: 88-100 %).115 
DGCD: The Danish Gynecologic Cancer Database was established in 2005 and 
contains information on all patients diagnosed with any type of gynecologic cancer at 
Danish hospitals. Data is entered prospectively and contains information on patient 
demographics, surgical treatment, final cancer stage and histopathology. Compulsory 
data entering is published in annual reports after audit by the engaged hospitals. The 
coverage rate compared to patients registered in the Danish National Patient Register 
is reported to be 97 % in most years since initiation of the DGCD.116 A validation 
study regarding endometrial cancer reported 97.3 % completeness for the coverage of 
pathological and surgical variables.117 Completeness of data concerning epithelial 
ovarian cancer was 94.2 % in a validation study covering the first two years after the 
database was established.118  
DAD: The Danish Anesthesia Database was established in 2004 and comprises 
information obtained in relation to surgical procedures such as body mass index 
(BMI), American Society of Anesthesiologists (ASA) score and smoking status. DAD 
has not covered all departments throughout the period since 2004, which reduces the 
utility in nationwide studies. The database was used in study I for analysis in a sub 
cohort.  
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The Population Statistics Register: Contains information on vital and civil status, 
and migration in and out of Denmark since 1971. Data is retrieved from the Danish 
Civil Registration System.  
The Register of Causes of Death: Contains information on time, age, cause, manner 
and place of death of Danish citizens since 1970. Data is based on death certificates 
completed by physicians. Such certificates, stating the underlying cause of death are 
mandatory for all deceased Danish residents.119       
The Danish Cancer Register: Has since 1942 collected information on newly 
diagnosed cancer cases from clinical and pathology departments in Denmark.120 Cases 
are coded with cancer type and staging level according to the TNM classification of 
tumors.  
The Danish National Prescription Registry: Is a subset register under the Danish 
Register of Medicinal Products, where data on all prescription-based medicine 
claimed at Danish Pharmacies since 1994 is registered. Data contains CPR number, 
Anatomical Therapeutic Chemical (ATC) classification, total prescription dosage and 
date of dispensing.121,122 
The Danish Pathology Register: Established in 1997. Holds information on 
histopathological diagnoses obtained from pathologic examination of cell and tissue 
samples, including date and type of sampling procedure.123 Pathologic-anatomical 
diagnoses follow SNOMED pathology.124 
3.2. STUDY POPULATIONS 
Study I is based on data retrieved from the DNPR and linked with other national 
registers. Study II-III are primarily based on data from the DGCD. Linkage of 
different registers using encrypted CPR numbers provided us with unique datasets 
with various variables allowing us to study the causal relationships between 
gynecologic cancers and VTE. Study IV is based on a local prospectively included 
cohort of patients with suspected ovarian cancer, referred to the Department of 
Gynecology and Obstetrics at Aalborg University Hospital for diagnosis and 
treatment. 
3.2.1. LOCAL COHORT FROM AALBORG UNIVERSITY HOSPITAL 
(STUDY IV) 
Patients referred to the Department of Gynecology and Obstetrics at Aalborg 
University Hospital in the period from Dec 2014 - May 2017 were evaluated for 
inclusion in the clinical trial. Inclusion criteria were suspected ovarian cancer 
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(pathologic pelvic mass and RMI ≥200 calculated with the formula suggested by 
Tingulstad et al.81) and written informed consent. Exclusion criteria were connective 
tissue disease, previous (within three years) or concomitant cancer, and current 
treatment with anticoagulant medicine. Baseline data was obtained by the gynecologic 
oncologist at time of first referral. Patients underwent systematic VTE examination 
within a few days after their first visit in the outpatient clinic. Patients were routinely 
examined with a 18F-FDG PET-CT for diagnostic and preoperative evaluation. CT of 
the thorax was performed in arterial phase ensuring state of the art diagnosis of 
possible pulmonary embolisms. Objective examinations for DVT with CUS were 
performed at time of diagnosis, on day 1 or 2 after surgery and repeated 1, 6 and 12 
months after inclusion. Extra CUS and/or CTPA was performed if indicated by 
symptoms, and/or elevated D-dimer levels. 
Per-operative frozen section was undertaken by expert gyneco-pathologists for initial 
diagnosis. Fractions of fresh frozen as well as paraffin embedded tumor tissue were 
collected and stored in the DCB and reserved for later analysis of protein profiling of 
different histotypes and a possible link to risk of VTE risk.  
Blood samples were collected at time of diagnosis, 1-2 days postoperatively, and after 
1,3,6 and 12 months. Cubital venipuncture followed European Concerted Action on 
Thrombosis (ECAT) procedures.125 Routine blood analyses were performed on the 
day of attendance (infection parameters, hematology, liver-enzymes, CA-125 and 
coagulation markers). D-dimer analysis was carried out with the BCS XP system from 
Siemens using the MediRox reagent (D-dimer cut-off level used was 0.3 mg/l). Whole 
blood was distributed in 2 mL EDTA plasma, 4 mL EDTA whole blood, 2 mL serum 
and 10 mL citrate plasma. Blood samples for storage in the DCB were centrifuged at 
2500 x g for 15 minutes before the supernatant was transferred to another tube 
followed by a second centrifugation, and the supernatant was transferred to micro 
tubes and frozen immediately at -80°C. 
For comparison, data on patients referred to the department in the same period, but 
not included in the study, was retrieved from the patient files with approval from the 
local ethics committee. The two cohorts are referred to as participants and non-
participants in the clinical trial.    
3.2.2. SOURCES OF INFORMATION IN STUDY I-III  
Benign indications for hysterectomy by ICD-10 codes: Uterine myomas (D25), 
Abnormal uterine bleeding (N92), pelvic organ prolapse (N81), endometriosis (N80), 
benign ovarian neoplasm (D27), pelvic pain (N94, R10), endometrial hyperplasia 
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(N850), urinary incontinence (R329), cancer predisposition (Z815, Z803), cervical 
intraepithelial neoplasia (N87) if coded at discharge following hysterectomy. 
Comorbidities by ICD-10 codes: Ischemic heart disease (I20, I23-25), cerebrovascular 
disease (I60-69), history of acute myocardial infarction (I21), thrombophilia(D68), 
varicose disease(I83), heart failure (I50), chronic obstructive lung disease (J44), 
diabetes (E10-14) if registered at discharge within 365 days before hysterectomy.  
Cancer diagnosis by ICD-10 codes: Cancer diagnosis (C00-96) were retrieved in order 
to exclude cancer patients. For validation and date of diagnosis in ovarian cancer 
(C48, C56-57) and cancer corpus uteri (C54-55). 
Cancer stage: Data was primarily retrieved from the DGCD, endometrial cancer stage 
followed the FIGO-2009, whereas ovarian cancer was coded according to FIGO-
2014126,127. In case of missing data in the DGCD, data on TNM stage was collected 
from the Cancer register and translated into FIGO stage (algorithm provided in 
appendix).  
Histopathology and differential grade: Retrieved from the Pathology Register in case 
of missing data in DGCD. 
Medicine by ATC codes: Use of specific pharmacotherapeutics within 180 days 
before surgery was based on at least one prescription of: Estrogen containing oral 
contraceptives (G03A, G03CB), hormone therapy with estrogen, oral and transdermal 
but not vagitories, (G03F, G03CX, G03CA, G03CB), antiplatelet drugs (B01AC), 
anticoagulating drugs (B01 except B01AC), glucose-lowering agents (A10).  
Postoperative LMWH: DNPR registration (BOHA03C). 
Surgery based on NOMESCO classification: Abdominal hysterectomy (KLCD00, 
KLCD96, KLCC10), laparoscopic hysterectomy (KLCD01, KLCD04, KLCC11, 
KLCD11, KLCD97, robotic-assisted +KZXX0), vaginal hysterectomy (KLCD10, 
KLCC20), radical hysterectomies (KLCD30, KLCD31, KLCD40), laparotomy 
(KJAH00), laparotomy with biopsies (KJAA10), lymphadenectomy (KPJD), 
extensive peritoneal exenteration (KJAQ00). 
Chemotherapy and VEGF-inhibitor registered in DNPR: Basic chemotherapy 
(BWHA1), BWHA (complex chemotherapy), VEGF-inhibitor (BOHJ19B). 
BMI by ICD-10 code or registered in a database: Overweight/obesity (DE660). 
Outcome by ICD-10 code: PE (I26), DVT (I80.1-I80.9) were registered as an event 
in study I and II if registered in the 30-day period following hysterectomy and in study 
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III if VTE occurred after EOC diagnosis. VTE episodes occurring before these dates 
were registered as previous VTEs.  
3.3. POTENTIAL CONFOUNDING 
An open-source software DAGitty, was used to visualize the causal assumptions and 
identify confounders that should be controlled for.128 The use of Directed Acyclic 
Graphs (DAGs) in epidemiologic research was introduced by Greenland et al. as a 
tool for visualization of causal assumptions.129 This can serve as a help to identify 
possible confounders present in observational studies as no test exists that can 
determine if a variable is a confounder. Three criteria should be fulfilled; The variable 
should be 1) a risk factor for the outcome of interest, 2) associated with the main 
exposure, 3) not on the causal pathway between main exposure and outcome.130 
Examples of simple DAGs are depicted in figure 8 and 9. Arrows indicate causal 
pathways between different factors, arrows and their directions are based on existing 
knowledge, interpretation and beliefs of the researcher.131 No factors can be self-
causal; thus, closed loops cannot be formed. A backdoor path is formed when an arrow 
head points from a confounder to exposure and from confounder to outcome. A 
backdoor path should be closed by controlling for the confounder, in DAG 
terminology “conditioning” on the confounder.132 A collider is a common effect 
indicated by two arrowheads pointing from outcome and exposure to the collider, this 
blocks the path. Conditioning on a collider opens the backdoor path and introduces 
selection bias.133 All other paths than the directed path between exposure and outcome 
should be blocked to avoid confounding. It should be kept in mind that a DAG is 
subject to the personal assumption of the researcher, but still a useful tool for 
identification of confounders to control for.  
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Figure 8 DAG example 1: Main exposure of interest is illustrated by the green circle, the green arrow 
represents the causal relations we want to investigate between exposure and outcome (blue circle). The red 
arrows illustrate a backdoor pathway that we need to block to avoid confounding, this means we have to 
adjust for the confounder (red circle) in our analysis.   
	
Figure 9 DAG example 2: Illustrating two causal path ways (green arrows) from exposure to outcome with 
an intermediate variable on one of them, this pathway should be kept open as conditioning on the 
intermediate would introduce over adjustment bias. The confounder is already adjusted for, indicated by 
the white circle and black arrows. The grey circle represents a collider on a blocked pathway (black arrows 
pointing in the direction of the collider), conditioning on the collider would open this pathway, thus 
introducing selection bias.
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3.4. STROBE 
Publication of the results from the four studies included in the PhD thesis adhered to 
the Strengthening the Reporting of Observational Studies in Epidemiology 
Statement.134 
3.5. STATISTICS 
Data management in study I-III was carried out using SAS V.9.4 (SAS Institute, Cary, 
North Carolina, USA). Calculations were performed using R version 3.4.0 (R Core 
Team, 2017).135 Stata version 13 was used in study IV. Estimates in regression 
analysis were presented with 95 % confidence intervals. P-values ≤ 0.05 were 
considered statistically significant. The Aalen-Johansen estimator was used to depict 
the cumulative incidence of VTE considering death as competing risk. 
STUDY	I	
Patients entered the study at the date of hysterectomy for benign disease and were 
followed for 30 days after surgery or until VTE event or death occurred. The 
cumulative incidence of VTE according to open, laparoscopic and vaginal 
hysterectomy was calculated considering the competing risk of death. Cox 
proportional hazard regression was used for univariable and multivariable analysis. 
The proportionality assumption was examined using plots of Schoenfeld residuals. 
Interaction between the presence of fibromyomas and approach to hysterectomy was 
tested using analysis of variance. Linearity between the outcome and the continuous 
variable age was tested. 
STUDY	II	
Patients were followed from the date of hysterectomy for endometrial cancer or 
benign disease until time of VTE event, death or 30 days after surgery. Cumulative 
incidence of the competing risks of VTE and death was calculated and depicted in the 
four exposure groups: Open hysterectomy for cancer, MIS for cancer, open 
hysterectomy for benign disease and MIS for benign disease. Descriptive statistics 
were carried out using analysis of variance for continuous variables and the chi-
squared test for categorical variables. Odds ratios of VTE were estimated using a 
multivariable logistic regression model. The adjusted model included assumed 
confounders primarily assessed by a directed acyclic graph and afterwards analyzed 
in a univariable model. 
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STUDY	III	
Patients were followed from the date of ovarian cancer diagnosis until VTE, death, 
emigration or end of follow-up (Dec 31st, 2018). Person-time at risk was calculated 
and baseline characteristics were expressed as person years, crude numbers and 
percentages. The 2-year incidence rate of VTE was estimated using Poisson 
regression analysis and presented as events per 1000 person years. 
Age and treatment for ovarian cancer were considered as time-varying exposures in 
time-to-event analyses. The impact of patient-, tumor-, and treatment related exposure 
on the risk of VTE was analyzed in a Cox proportional hazard regression model. The 
proportionality assumption was examined using plots of Schoenfeld residuals. 
STUDY	IV	
When planning the study, we calculated a sample size to ensure statistical 
significance. Based on a previous study in the Northern Jutland Region, we assumed 
that 1/3 of patients with suspected ovarian cancer based on RMI score ≥ 200, would 
be diagnosed with a benign tumor.136 Two Japanese studies using CUS for 
preoperative DVT screening found 3.5 % VTE cases in patients with benign ovarian 
tumors and 25 % VTE cases in EOC and borderline patients respectively.13793 
Considering the high prevalence of clear cell carcinomas in the Japanese cohort, our 
null hypothesis was 3.5 % VTE events in patients with benign ovarian tumors vs. 20 
% VTE events in patients with EOC and borderline tumors. We used Fisher’s exact 
test to calculate the sample size with a power of 0.80 and a two-sided significance 
level at 0.05 and concluded that we should include at least 47 with benign tumors and 
94 with malignant tumors. Inclusion was discontinued after a 2.5-year long inclusion 
period, at which point 97 patients had entered the study. The reason for 
discontinuation was primarily that the Department of Nuclear Medicine replaced their 
PET-CT equipment and would not be able to run the CTPA protocol for several 
months. Furthermore, interim results revealed that recruitment was slow and VTE 
incidence much lower than expected, indicating that we would need a much longer 
inclusion period and a larger cohort to achieve statistical power.  
Differences within the EOC cohort was tested using Fisher’s exact test for discrete 
variables and Wilcoxon rank sum for numerical variables. Cumulative incidence was 
graphical depicted for the competing risks of VTE and death.
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3.6. ETHICS 
Study I-III were carried out using encrypted personal data in the research environment 
of Statistics Denmark, permission from the ethics committee is not required for this 
type of study.  
The Danish Data Protection Agency approved study I with the reference (Re: 2007-
58-0015, int.ref: GEH-2010-001) and study II and III with the reference (Re: 2008-
58-0028, internal reference: 2015-125). 
The local Committee on Health Research Ethics, Northern Jutland Region (re: N-
20140009) and The Danish Data Protection Agency (re: 2008-58-0028) approved 
Study IV which was also registered at ClinicalTrials.gov (identifier: NCT02480790).
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RESULTS
STUDY	I	
A total cohort of 89,931 women undergoing hysterectomy for a benign disease in the 
period Jan 1st 1996 to Dec 31st 2015 were included in the study.138 Three different 
exposure groups were examined with regards to route of hysterectomy: Open 
(n=59,231), laparoscopic (n=9,198), and vaginal (n=21,502). There was an increasing 
tendency to perform MIS in favor of open hysterectomy during the study period. 
Venous thromboembolic complications in the 30-day postoperative period were rare, 
with an overall incidence at 0.19 %. Lowest was with a vaginal approach (0.10 %) vs. 
0.13 % with laparoscopy and 0.24 % with open hysterectomy. When adjusting for 
assumed confounders in a multivariable Cox regression model, the risk of VTE was 
significantly lower in laparoscopic (HR=0.51; 95 % CI, 0.28-0.92, p=0.03) and 
vaginal (HR=0.39; 95 % CI, 0.24-0.63, p<0.001) compared to open hysterectomy. A 
sub-cohort of patients undergoing hysterectomy after 2003 was investigated to 
estimate the effect of LMWH thrombosis prophylaxis which was introduced in the 
national guideline for hysterectomy, published by the Danish National Board of 
Health in 2003139. The HR of VTE in patients receiving LMWH prophylaxis was 0.63 
(95 % CI, 0.42-0.96, p=0.03) compared to non-exposed. Crude and adjusted HRs of 
VTE in different exposure groups are provided in Table 1. 
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Table 1 Cox proportional hazards models for venous thromboembolism in different exposure groups.138 
 
STUDY	II	
A study population consisting of 45,825 patients with benign gynecological disease 
and 5,513 patients with endometrial cancer undergoing hysterectomy in the study 
period from Jan 1st 2005 to Dec 31st 2014, were included.140 The incidence of VTE in 
four different exposure groups was calculated: Open hysterectomy for endometrial 
cancer (21/3,377~0.6 %), MIS for endometrial cancer (9/2,136~0.4 %), open 
hysterectomy for benign disease (52/22,401~0.2 %) and MIS for benign disease 
(21/23,424~0.1 %). Variables to fit a logistic regression model were selected based 
on DAGs, as depicted in Figures 10 and 11. 
 
 VTE events/N total HR, Crude (95 % CI) HR, multivariable (95 % CI) 
Main exposures    
Abdominal hysterectomy 142/59,231 Reference Reference 
Laparoscopic hysterectomy 12/9,198 0.54(0.30-0.98) 0.51(0.28-0.92) 
Vaginal hysterectomy 21/21,502 0.41(0.26-0.64) 0.39(0.24-0.63) 
Confounders    
Age (by decade) 175/89,931 1.16(1.02-1.31) 1.06(0.93-1.21) 
Benign ovarian tumors 11/5,391 1.05(0.57-1.94) 0.75(0.40-1.40) 
Uterine fibroids 76/43,051 0.83(0.62-1.13) 0.82(0.60-1.13) 
Hormone therapy 24/12,931 0.95(0.62-1.46) 1.10(0.69-1.74) 
Contraceptives 13/6,596 1.01(0.58-1.78) 1.35(0.75-2.40) 
Anticoagulant drugs 31/918 21.5(14.6-31.7) 2.22(1.40-3.53) 
Previous AMI 6/573 5.7(2.5-12.8) 2.57(1.12-5.94) 
Previous VTE  67/1,540 36.7(27.1-49.8) 26.8(18.6-38.7) 
 
Surgery after 2003 
 
105/53,566 
 
1.02(0.75-1.38) 
 
0.93(0.68-1.28) 
 
Postoperative VTE prophylaxis  
 
43/31,391 
 
0.49(0.33-0.72) 
 
0.63(0.42-0.96) 
Abbreviations: VTE, venous thromboembolism; AMI, acute myocardial infarction. 
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Figure 10 DAG illustrating causal pathways highlighted in green color with operative time and length of 
hospital stay as intermediate variables. Black arrows illustrate backdoor pathways. 
  
Figure 11 DAG illustrating colliderbias in a situation where length of stay is a collider, thus introducing 
bias if controlled for. 
The adjusted OR of VTE was not significantly higher in endometrial cancer patients 
compared to patients undergoing hysterectomy for benign disease (1.47; 95 % CI, 
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0.74-2.91; p=0.27). Independent risk factors associated with 30-day risk of VTE were: 
open hysterectomy, BMI>40, lymphadenectomy and previous VTE (Fig. 12). 
 	
Figure 12 Odds ratios of venous thromboembolism in relation to potential risk factors. Modified from140 
STUDY	III	
A cohort of 4,991 patients diagnosed with EOC were included and followed in this 
trial, collectively contributing with 20,214 person years from time of diagnosis till 
VTE event, death or right censoring.141 Patient selection is illustrated in figure 13. 
																						 
Figure 13 Flowchart for patient selection using nationwide Danish registries. Modified from141 
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Danish women diagnosed with ovarian 
cancer (2005-2014) 
N = 5,279 
 
Patients excluded;  
Sarcomas (n=29)  
Germ cell tumors (n=84)   
Sex cord stromal tumors (n=138) 
Incomplete follow-up data due to temporary 
civil registration number (n=37) 
 
Patients with epithelial ovarian cancer 
Serous (n=2629) 
Endometrioid (n=412) 
Mucinous (n=302) 
Clear cell (n=212) 
Other epithelial (n=1244) 
Missing histopathology (n=192) 
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During a median follow-up of 2.9 years 551 VTE events were observed corresponding 
to 27 VTEs per 1000 person years (95 % CI, 25-29). Risk of VTE was associated with 
increasing age, previous VTE, advanced FIGO stage, clear cell histopathology, 
surgery and chemotherapy (Figure 14). 
	
Figure 14 Hazard ratios associated with patient-, tumor- and treatment related risk factors. From141 
STUDY	IV	
During the inclusion period from Nov 2014 to May 2017 a total of 221 patients 
referred to the department of Gynecology and Obstetrics, Aalborg University Hospital 
on suspicion of ovarian cancer were assessed for inclusion in the trial.142 Written 
informed consent was obtained from 97 patients, of whom 33 were later diagnosed 
with benign ovarian tumors, 11 with borderline malignancies and 53 with epithelial 
ovarian carcinomas. Non-participants tended to be older and had more co-morbidities. 
In EOC participants 3.8 % had VTE at time of diagnosis, whereas 4.2 % of non-
participants had pre-treatment VTE. One-year cumulative incidence of VTE in EOC 
patients was 20.8 % in the cohort that underwent systematic objective VTE 
examination (participants) and 18 % in non-participants (fig. 15 and 16). Mortality 
was highest in non-participants. Median time to VTE was 87 (0-358) and 71 (0-184) 
days, respectively. Information on presentation and timing of VTE events in relation 
to treatment is provided in table 2. 
Age group
Previous VTE
FIGO stage
Histology
Surgery
NACT
Chemotherapy
VEGF−inhibitor
Years since EOC
<60
60−69
70−79
>79
No
Yes
I−II
III−IV
Unknown
Non−CCC
CCC
No
Yes
No
Yes
No
Yes
No
Yes
0−1
1−2
2−3
>3
144/6324
171/6188
166/5422
70/2280
478/19709
73/505
123/9879
414/10004
14/331
520/19090
31/1123
503/19861
48/353
544/20158
7/56
384/17454
167/2760
540/19885
11/328
257/4224
104/3329
62/2711
128/9950
0.428
0.024
0.013
<0.001
<0.001
0.006
0.042
<0.001
0.136
<0.001
0.919
0.131
0.003
<0.001
Variable Units Events/PY P−value
Ref.
1.10 [0.87;1.39]
1.31 [1.04;1.66]
1.46 [1.08;1.97]
Ref.
3.87 [2.91;5.14]
Ref.
2.47 [1.98;3.10]
2.27 [1.27;4.07]
Ref.
1.52 [1.01;2.28]
Ref.
3.19 [2.27;4.47]
Ref.
1.98 [0.81;4.87]
Ref.
1.90 [1.56;2.32]
Ref.
1.03 [0.56;1.89]
Ref.
0.82 [0.64;1.06]
0.63 [0.46;0.85]
0.49 [0.37;0.64]
Hazard Ratio (95% CI)
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Figure 15 Cumulative incidence of VTE in EOC patients participating in the clinical trial with 
consequent examination for VTE, death is competing risk. Modified from142. 
 
Figure 16 Cumulative incidence of VTE and death in non-participants. Unpublished plot from 142 
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Table 2 Comparison of participants and non-participants according to localization and timing of VTE. 
Modified from142 
 
 
Variablea Participants (11) Non-participants (13) 
VTE location   
Proximal DVT 4(36.3) 4(30.7) 
Central and segmental PE - 2(15.4) 
Subsegmental PE 3(27.3) 3(23.1) 
DVT + PE 3(27.3) 2(15.4) 
VTE at central vein catheter site 1(9.1) 1(7.7) 
Ovarian vein thrombus - 1(7.7) 
Symptomatic vs. incidental   
Symptomatic 5(45.5) 7(53.8) 
Incidental 6(54.5) 6(46.2) 
Timing of VTE   
Median time to VTE, days (range) 87 (0-358) 71(0-184) 
Before treatment 2(18.1) 3(23.1) 
 
Postoperative VTE 1(9.1) 1(7.7) 
During neoadjuvant chemotherapy 3(27.3) 4 (30.8) 
During adjuvant chemotherapy 3(27.3) 2(15.4) 
During palliative chemotherapy 1(9.1) 3 (23) 
During randomized trial with PARP- 
inhibitor/placebo                                       
1(9.1) - 
Abbreviaions: VTE, Venous thromboembolism; DVT, Deep vein thrombosis; PE, Pulmonary embolism; PARP, Poly ADP Ribose Polymerase 
a Data are expressed as No. (%) unless otherwise indicated.                          
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Baseline D-dimer levels measured in blood samples collected before treatment was 
initiated are depicted in Figure 17. D-dimer levels were normal in most patients with 
benign ovarian tumors and elevated in the majority of EOC patients independent of 
the presence of current or future VTE event. 
 
 
Figure 17 Differences in pretreatment D-dimer levels in benign and malignant tumors. Blood samples 
collected from patients participating in study IV142. Dashed line indicates normal D-dimer level at 0.3 mg/l. 
Results previously presented at the 9th International Conference on Thrombosis and Hemostasis Issues in 
Cancer, April, 2018.143
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GENERAL DISCUSSION 
5.1. MAIN FINDINGS 
In the first study138, we found a low overall incidence of postoperative VTE following 
hysterectomy when indicated for benign disease, especially if the procedure was 
performed as MIS. In study II140, we investigated if the risk of VTE was higher in 
patients undergoing hysterectomy due to endometrial cancer compared to a sub-cohort 
of patients from study I. There was no statistically significant difference. 
Study III confirmed previous reports of a high incidence of VTE in epithelial ovarian 
cancer. We were able to investigate several recognized risk factors in a multivariable 
time-dependent analysis by including a large cohort from a national database.141  The 
results give a good indication of the impact of the various risk factors in a Caucasian 
cohort.  
We objectively assessed occurrence of VTE in study IV with the aim of clarifying if 
asymptomatic VTE was present at time of diagnosis and followed by progression to 
symptomatic VTE after anticancer treatment.142 The study revealed a low incidence 
(3.8%) of pre-treatment VTE but a high cumulative incidence of VTE (20.8 %) 
throughout the first year after diagnosis. Median time to VTE was 87 days, with most 
events occurring during chemotherapy. In comparison, patients diagnosed with EOC 
at our department within the study period, but not included in the clinical trial, had a 
similar high one-year VTE incidence of 18 %.   
5.1.1. POSTOPERATIVE VTE (STUDY I, II AND III) 
Guidelines in gynecology and obstetrics recommended thrombosis prophylaxis in 
relation to surgery for several years. The American College of Gynecologists and 
obstetricians (ACOG) recommends a risk stratification, with LMWH administered to 
the majority except for healthy patients younger than 40 years of age, undergoing 
surgery for less than 30 min.144 In Denmark, LMWH prophylaxis was implemented 
for all patients undergoing hysterectomy after recommendations by the Danish 
National Board of Health in 2003.139 Recommendations are primarily based on RCTs 
including patients undergoing open surgery for various diseases.144–146 An early 
multicenter study by Kakkar et al. (1975) observed a difference in postoperative DVT 
incidence of 8 % vs. 25 % in patients exposed to low-dose heparin from two hours 
before surgery and 7 days after surgery compared to the control group.147 Patients in 
this study underwent open surgery for different benign and malignant conditions and 
VTEs were diagnosed by phlebography, radioactive fibrinogen screening test, chest 
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X-ray or autopsy in case of death. Furthermore, currently updated guidelines 
recommend four weeks of extended prophylaxis for all patients undergoing surgery 
for solid cancers. Despite clear recommendations of thrombosis prophylaxis, 
observational studies based on data from clinical registries reveal a low adherence to 
the guidelines. Two studies showed no significantly higher VTE incidence in patients 
who did not receive pharmacologic prophylaxis, compared to those who did.65,148 
However, nearly half of the patients in the study by Ritch et al. did receive mechanical 
prophylaxis with elastic compression stockings or intermittent pneumatic 
compression, giving rise to an expectation that VTE incidence would have been higher 
with no prophylaxis at all.148 Another study by Bouchard-Fortier et al. found a 30-day 
VTE incidence of 0.57 % following MIS for gynecologic cancer even though 84 % of 
patients did not receive any kind of prophylaxis.149 An editorial by Clarke-Pearson 
and Barber addressed the lack of knowledge regarding proper VTE prophylaxis in 
gynecologic oncology surgery since current recommendations are mainly 
extrapolated from other surgical fields.66 Barber et al. propose the development of a 
risk assessment model for use in gynecologic oncology surgery as the available tools 
from general surgery are not very applicable in gynecology.150 
In all studies, we defined the postoperative period as the first 30 days after surgery, so 
our results were comparable with similar studies.39,151 We chose this approach, even 
though surgery is categorized as a major transient risk factor  that increase risk of VTE 
for 12 weeks following surgery.5,13 
The incidence of 30-day postoperative VTE was very low in study I, especially when 
performed as MIS.138 Patients exposed to LMWH prophylaxis had a significantly 
lower risk of VTE. A prior VTE was associated with a substantial increased risk of 
VTE in study I, II and III, illustrating the importance of including this factor in the 
risk assessment. Risk of VTE was not significantly higher in patients undergoing 
hysterectomy for endometrial cancer compared to benign disease in study II.140 This 
cancer type is associated with risk factors that could also increase risk of VTE such 
as high age and BMI, hence the results have been controlled for these factors.13 Crude 
results showed higher VTE incidence in endometrial cancer patients while adjusted 
results showed no significantly higher risk. Surgery was the most important treatment-
related risk factor in study III. 
5.1.2. OVARIAN CANCER AND RISK OF VTE (STUDY III+IV) 
Several risk factors, including biological mechanisms and timing of events, have been 
proposed regarding VTE in ovarian cancer.100,152–155 Results from our research group 
have suggested that some postoperative VTE cases reported in clinical trials were 
present before surgery, induced by the cancer itself rather than the surgical trauma46,47 
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Satoh et al. revealed a very high (25 %) preoperative VTE incidence in patients with 
ovarian cancer and borderline tumors.93 Other studies from Japan have reported 
similar high pre-treatment incidences of VTE.156–158 The incidence of pre-treatment 
VTE was lower than expected in study IV, compared to recently published studies 
from Japan, but similar to an older German study with objective assessment of DVT 
incidence 92. Analyzing the data from study III and IV revealed that a Danish cohort 
of EOC patients is not comparable to Japanese cohorts, since the distribution of 
histopathologic subtypes is vastly different73,141,142, greatly impacting VTE risk. 
Furthermore, definitions of DVT vary between studies, resulting in overestimation of 
the VTE risk as some studies include intramuscular, and even superficial vein 
thrombosis in their definition of DVT. These thrombi do not carry the same risk of 
progression or recurrence as deep vein thrombosis. Accordingly, they are treated 
differently in existing clinical guidelines.159,160 Study IV was underpowered and could 
not elucidate differences in the risk of VTE between recognized risk factors, but gave 
a good implication of the timing of VTE events in relation to treatment. D-dimer levels 
measured in patients in study IV confirmed the poor accuracy of this test to rule out a 
VTE event in EOC patients.93 In study III, we were able to investigate the association 
between EOC and VTE controlling for recognized risk factors. Among tumor-related 
risk factors we found that advanced FIGO stage was stronger associated with VTE 
than clear cell histopathology. Regarding treatment related VTE, EOC patients had a 
more than three-fold risk of VTE in the 30-day post-operative period and a two-fold 
risk during chemotherapy.  
5.2. METHODOLOGICAL CONSIDERATIONS 
5.2.1. SYSTEMATIC ERRORS 
SELECTION	BIAS	
Selection bias occurs when the investigated sample is not representative of the target 
population. This is rarely a problem in population based cohort studies with complete 
follow-up as it was the case in study I-III. We investigated the risk of VTE after 
hysterectomy in study I and II and noticed that other studies on the same subject 
included length of hospital stay (LOS) in the multivariable analyses. 39,151 We did not 
control for LOS in study I and II as DAGs (Fig. 10 and 11) illustrated that LOS could 
act as either an intermediate or a collider if the increased LOS was actually a result of 
a postoperative VTE. Conditioning on LOS would then introduce selection bias. 
Selection bias is likely present in study IV, since EOC patients agreeing to participate, 
had a lower mortality than non-participants. This phenomenon was previously 
described by Larsen et al.161 
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INFORMATION	BIAS	
Information bias arises if subjects included in a study are misclassified with regard to 
exposures, target disease or confounders. This type of bias is reduced in study I-III by 
use of validated register data of high quality. A high proportion of EOC non-
participants (18 %) in study IV were diagnosed with VTE during the study period, 
even though these patients were not systematically screened. An explanation for this 
finding could be that both clinicians and radiologists were more aware of this 
complication in EOC patients, due to the ongoing trial.   
CONFOUNDING	
Confounding is present when exposed and non-exposed individuals in a study are 
incomparable to differences in disease risk, because other risk factors are differently 
distributed within exposed and non-exposed. Knowledge about the associations 
between exposures and outcome is important, in order to determine which 
confounders to control for, since no test for confounding exists.162 We used DAGs in 
study I-III to guide the selection of confounders to control for in the multivariable 
analyses.129   
There are different ways to control for confounding in the design and analysis stages: 
One option is randomization, which is rarely possible in epidemiological studies, 
another is narrowing the number of potential confounders.130 We used the latter 
approach in study I, II and IV by excluding patients with malignant diseases other 
than the ones of interest within a certain time-frame, to minimize the effect from other 
cancers on VTE risk. Further exclusion criteria were defined in study IV, potentially 
contributing to not reaching our calculated sample size, since many patients did not 
meet the inclusion criteria. Furthermore, the generalizability of the results decreases 
with many exclusions, which was illustrated by the fact that mortality was 
considerably higher in EOC non-participants, diagnosed at the same department 
within the study period. Another way to control for confounding in the study design, 
is to match on specific variables to ensure the same proportion of exposed and 
unexposed subjects in the cohort. Control for confounding in the analysis can be 
carried out by stratification in case of few confounding factors, or by multivariable 
regression analysis allowing to control for several confounding factors limited by the 
number of events. In cases where data on a confounding variable is lacking e.g. type 
II diabetes mellitus treated in general practice, another variable might serve as “a 
proxy”. Dispensing of glucose-lowering agents was used in study II to ensure correct 
classification of diabetes patients included in a sub-analysis to estimate the effect of 
comorbidities, as it has been done previously.163  
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Despite adjusting for known confounders, there might still be residual confounding 
from unmeasured or unknown factors.113   
 
5.2.2. RANDOM ERRORS 
Observational studies investigate associations between exposures and outcome based 
on a sample from a population, assuming that we can draw conclusions about the 
causal inference regarding the entire population. A random error may lead to 
inaccurate estimates of disease frequency and associations between exposures and 
outcome. A method of reducing this type of error is to increase the study population, 
which is not always possible in epidemiologic studies where sample size is based on 
the available data. Confidence limits to the estimates indicate the degree of 
precision.130 We were able to include large nationwide cohorts in the epidemiological 
studies (I-III) and our findings are not likely to be subject to chance. Study IV was 
underpowered to estimate associations between recognized risk factors and VTE 
within EOC patients.
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CONCLUSIONS AND IMPLICATIONS 
OF THE THESIS 
STUDY	I	
In conclusion, we found a low risk of VTE in a large cohort of women undergoing 
hysterectomy for benign disease. Risk factors were open surgery, treatment with 
anticoagulant drugs and previous venous and arterial thromboembolic events. 
Exposure to postoperative prophylactic LMWH was associated with a significant 
lower risk of VTE. 
STUDY	II	
The risk of VTE was low after hysterectomy for endometrial cancer and statistically 
not significantly different from the risk when hysterectomy was performed for benign 
disease. Independent risk factors were open surgery, BMI>40, lymphadenectomy, and 
previous VTE.  
STUDY	III	
The risk of VTE was high among EOC patients especially within the first year after 
diagnosis. Advanced FIGO stage was associated with a higher VTE risk than clear 
cell histopathology in a Danish EOC cohort. Major surgery was associated with a 3-
fold increase of VTE, while chemotherapy was associated with a 2-fold higher risk 
compared to non-exposed.  
STUDY	IV	
The cumulative incidence of VTE within the first year after diagnosis was 20.8 % in 
EOC patients undergoing systematic examination for VTE. Pretreatment VTE 
incidence was lower (3.8 %) than expected, based on recent Asian publications. 
Median time to event was 87 days, with the majority of VTEs occurring during non-
surgical anti-cancer treatment. 
The studies in the thesis investigated the risk of VTE in gynecologic patients treated 
for various benign and malignant diseases. The studies give a good indication that the 
risk of postoperative VTE is low after hysterectomy for benign conditions and 
endometrial cancer. Epithelial ovarian cancer carries a high risk of VTE, particularly 
in the first year after cancer diagnosis. Future research should focus on elucidating 
subgroups of patients that would benefit from further extension of prophylaxis. 
DISCUSSION 
58 
 
59 
PERSPECTIVES 
The findings in study I and II indicate that the risk of VTE is very low after 
hysterectomy for benign conditions and endometrial cancer. With an apparently 
insignificant difference in the risk of postoperative VTE in endometrial cancer 
patients compared to patients undergoing hysterectomy for benign conditions, it might 
not be necessary to prescribe extended LMWH prophylaxis to all patients. Further 
investigations should clarify if patients could be additionally stratified further into risk 
categories regarding risk of postoperative VTE. A randomized controlled trial would 
be ideal in order to clarify if pharmacologic VTE prophylaxis is indicated to all 
patients undergoing MIS. A large sample size is required and fund raising for such a 
project would probably be difficult, as the results might not be beneficial to the 
medicinal industry. 
Molecular biology research will potentially lead to better understanding of the 
hypercoagulant state observed in at least some histopathologic subtypes of EOC. 
Tumor tissue was collected from patients included in study IV and proteomic analysis 
was performed in cases with VTE events and a control group, consisting of nine 
patients with clear cell carcinomas from the Danish Cancer Biobank, nine cancer 
patients and ten patients with benign ovarian tumors, included in the clinical trial. The 
interpretation of bioinformatics data is currently underway, and the study group 
expects to be able to publish the results in the near future. 
Blood samples collected from patients in study IV will be analyzed to evaluate the 
utility of novel coagulation markers to diagnose clinical and subclinical VTE in EOC 
patients. 
The knowledge gained within the field of epidemiologic research has prompted the 
author’s involvement in other research collaborations. One research project aims to 
describe the distribution of birth weight in a Danish national birth cohort and analyze 
the result in relation to international birth weight references.  
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Supplementary table 1 Algorithm for translating FIGO classification to TNM SKS codes55,69,126,164
 
FIGO Description TNM SKS T stage 
I Tumor confined to the corpus uteri T1N0M0 AZCD13 
IA Tumor limited to endometrium or myometrial invasion < 50 % T1aN0M0 AZCD13A 
IB Myometrial invasion ≥ 50 % T1bN0M0 AZCD13B 
II Invasion of cervical stroma, but no extension beyond the uterus  T2N0M0 AZCD14 
III Local and/or regional spreading T3N0M0 AZCD15 
IIIA Invasion of serosa of the corpus uteri and/or adnexae T3aN0M0 AZCD15A 
IIIB Involvement  of vagina and/or parametrium T3bN0M0 AZCD15B 
IIIC Pelvic and/or para-aortic lymph node metastases T1-T3, N1, 
N1mi,or N1a, M0 
AZCD15C 
IIIC1 Positive pelvic nodes T1-T3, N2, 
N2mi,or N2a, M0 
AZCD15C 
IIIC2 Positive para-aortic nodes with/without positive pelvic nodes T1-T3, N2, 
N2mi,or N2a, M0 
AZCD15C 
IV Invasion of bladder and/or bowel mucosa, and/or distant metastases T4N0M0 AZCD16 
IVA Invasion of bladder and/or bowel mucosa T4, Any N, M0 AZCD16A 
IVB Distant metastases, including intraabdominal metastases and/or 
inguinal lymph nodes  
Any T, Any N, M1 AZCD16B 
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